Jainil Shah, MD
Interventional Cardiology · Pine Bluff, ARNPI 1225478472
Payments from drug & device makers
Across 408 payments — averaging $35.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Penumbra, Inc.$3K
- Shockwave Medical, Inc$3K
- Abbott$1K
- Novartis$975
- Merck$681
- Abiomed$638
- plus $5K from 33 others
What the payments were for
- Travel & lodging$2,73319%
- Food & beverage$11,51080%
- Education$1471%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Penumbra, Inc. | 12 | $2,885 |
| Shockwave Medical, Inc | 29 | $2,679 |
| Abbott | 11 | $1,263 |
| Novartis | 73 | $975 |
| Merck | 34 | $681 |
| Abiomed | 8 | $638 |
| Amgen | 38 | $592 |
| Johnson & Johnson | 32 | $574 |
| Pfizer | 30 | $445 |
| E.r. Squibb & Sons, L.L.C. | 18 | $378 |
| Alnylam Pharmaceuticals Inc. | 11 | $339 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 12 | $325 |
| Medtronic(2 entities) | 8 | $289 |
| Boston Scientific | 7 | $278 |
| Scpharmaceuticals Inc. | 8 | $182 |
| Edwards Lifesciences | 1 | $173 |
| Lexicon Pharmaceuticals, Inc. | 9 | $165 |
| AstraZeneca | 10 | $150 |
| Baxter Healthcare | 3 | $129 |
| Acist Medical Systems, Inc. | 1 | $127 |
| GSK | 8 | $124 |
| Boehringer Ingelheim | 6 | $101 |
| Philips North America LLC | 6 | $96 |
| Cardinal Health 200 LLC | 2 | $92 |
| Cardiovascular Systems Inc. | 1 | $84 |
| Actelion Pharmaceuticals US, Inc. | 4 | $82 |
| Bayer | 4 | $77 |
| Mallinckrodt Hospital Products Inc. | 3 | $63 |
| Irhythm Technologies, Inc. | 3 | $58 |
| Heartflow, Inc. | 1 | $57 |
| Esperion Therapeutics, Inc. | 4 | $55 |
| Novo Nordisk | 2 | $43 |
| Bridgebio Pharma, Inc. | 2 | $38 |
| Sanofi-aventis U.S. LLC | 2 | $33 |
| Cvrx, Inc. | 1 | $26 |
| Kestra Medical Technology Services, Inc. | 1 | $25 |
| Elutia, Inc. | 1 | $23 |
| Akebia Therapeutics Inc | 1 | $22 |
| Cardiva Medical, Inc. | 1 | $22 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Indigo System$2,832
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$1,823
- OPTIS$725
- Impella$367
- PASCAL$173
- COROFLOW$146
- CVI SYSTEMS$127
- AMVUTTRA$121
- HeartMate 3 Left Ventricular Assist Device$119
- ELIQUIS$106
- LifeVest$103
How this compares
$14,389 in reported general payments places this provider in the 75th percentile of 89 interventional cardiology providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EntrestoSacubitril/Valsartan | 142 | $141,780 |
| EliquisApixaban | 97 | $75,060 |
| XareltoRivaroxaban | 75 | $57,689 |
| FarxigaDapagliflozin Propanediol | 74 | $51,953 |
| BrilintaTicagrelor | 43 | $30,173 |
| JardianceEmpagliflozin | 22 | $19,315 |
| Repatha SureclickEvolocumab | 15 | $16,604 |
| VerquvoVericiguat | 11 | $8,550 |
| Metoprolol Succinate | 531 | $4,039 |
| Chlorthalidone | 112 | $1,750 |
| Losartan Potassium | 255 | $1,696 |
| ClopidogrelClopidogrel Bisulfate | 201 | $1,493 |
| Amlodipine Besylate | 231 | $1,301 |
| Atorvastatin Calcium | 200 | $1,288 |
| Pravastatin Sodium | 136 | $1,158 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisEntresto | $975 | $141,780142 claims |
| AstraZenecaFarxiga, Brilinta | $150 | $82,125117 claims |
| PfizerEliquis | $445 | $75,06097 claims |
| Johnson & JohnsonXarelto | $574 | $57,68975 claims |
| Boehringer IngelheimJardiance | $101 | $19,31522 claims |
| MerckVerquvo | $681 | $8,55011 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 89 interventional cardiology providers in Arkansas.
Other interventional cardiology in Pine Bluff
- Mauro Taveras AlcantaraPine Bluff$8K
- Gaurav DharLittle Rock$793K
- Ernesto Ruiz-RodriguezLittle Rock$499K
- Joel CarverFayetteville$305K
- Vasili LendelLittle Rock$206K
- Vijay RajaLittle Rock$106K
- Thomas WattsLittle Rock$79K
- Lena AwarJonesboro$43K
- Zubair AhmedFayetteville$36K
- Stephen BroughtonLittle Rock$34K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.